[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Kallikrein Inhibitors 2017

April 2017 | 17 pages | ID: C4264E496D0EN
La Merie Publishing

US$ 170.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists

The present Competitive Intelligence report aboutKallikrein Inhibitors & Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and novel approaches for prophylaxis and treatment of hereditary angioedema (HAE) as of June 2014. Inhibitors of kallikrein and antagonists of the bradykinin receptors are based on small molecules, antibodies, proteins, peptides as well as RNA and their use is being extended to other diseases.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of small molecule, antibody, protein, peptide and oligonucleotide inhibitors or antagonists kallikrein or the bradykinin receptor, respectively. In addition, the report lists company-specific R&D pipelines of kallikerein inhibitors & bradykinin receptor antagonists. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. KALLIKREIN INHIBITORS

2. BRADYKININ RECEPTOR ANTAGONISTS

3. CORPORATE KALLIKREIN INHIBITOR & BRADYKININ RECEPTOR ANTAGONIST R&D PIPELINES


More Publications